Patients with diabetes show poor adherence therapy for heart disease

Adherence to heart disease drugs dopped by half within one year, increasing risks

May 21, 2019

Adherence to add-on therapies for heart disease dropped by half within one year for patients new to diabetes with heart disease, increasing risks for heart attacks or strokes

This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD.

  • Glucagon like peptide-1 agonists (GLP-1)
  • Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
  • Dipeptidyl peptidase-4 inhibitors (DPP-4i)

All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90 percent in their clinical trials.)

Read more.

Among Commercially Insured Members with Diabetes Mellitus (DM), Choice and Persistence of Drug Therapy: Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) Versus Glucagon-like Peptide-1 Agonists (GLP-1) or Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) (Fall 2018)

Related news

Perspectives

August 4, 2022

Specialty Pipeline Update: July 2022

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Perspectives

August 4, 2022

Traditional Drug Pipeline Update: July 2022

This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…

Perspectives

July 26, 2022

Working together to lead the way

We often have the impression that advancing and leading in your career requires…